Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes

PURPOSE: Oral agents are needed that improve glycemic control without increasing hypoglycemic events in patients with type 1 diabetes (T1D). Sotagliflozin may meet this need, because this compound lowers blood glucose through the insulin-independent mechanisms of inhibiting kidney SGLT2 and intestin...

Descripción completa

Detalles Bibliográficos
Autores principales: Powell, David R, Doree, Deon, Jeter-Jones, Sabrina, Ding, Zhi-Ming, Zambrowicz, Brian, Sands, Arthur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346285/
https://www.ncbi.nlm.nih.gov/pubmed/25759591
http://dx.doi.org/10.2147/DMSO.S76342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346285/
https://www.ncbi.nlm.nih.gov/pubmed/25759591
http://dx.doi.org/10.2147/DMSO.S76342

Ejemplares similares